Supriya Lifescience Limited has reappointed Dr. Neelam Yashpal Arora as a Non-Executive Independent Woman Director, with effect from March 25, 2026, subject to shareholder approval. The company has also appointed Manish Panchal and Kothandaraman Hari as Independent Directors (Additional Directors), effective February 9, 2026, subject to shareholder approval.
Dr. Neelam Yashpal Arora has more than 31 years of teaching experience and around 10 years of administrative experience in the education sector. Her areas of expertise include education, commerce, taxation, economics, and law. She holds a bachelor’s and master’s degree in commerce, bachelor’s and master’s degrees in law, and a PhD in commerce, all from the University of Mumbai.
Manish Panchal is associated with organisations such as IL&FS AMC Ltd., Nesco Ltd., the Patil Group, Vashi Integrated Solutions, Aaji Care Home Health Services Pvt. Ltd., Aaji Care Sevak Foundation, Arujiva, FICCI, Tata Strategic Management Group, and Abbott Laboratories. He has over 32 years of cross-industry experience spanning chemicals and new energy, logistics, pharmaceuticals, medical devices, and healthcare. He is active in investment banking and advises companies on capital raising and structured business growth.
Kothandaraman Hari is a capital markets professional with over 28 years of experience and has played a key role in the growth of the National Stock Exchange of India. As Executive Vice President at NSE, he led initiatives across multiple asset classes and contributed to regulatory and policy development. He is the founder of Onspin Consultants LLP and has served on the Boards of NSE Academy, NSE Cogencis, and the India International Bullion Exchange, contributing to governance, strategy, and risk oversight.
